Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines

Definitions

• This invention is concerned with the use of dopamine agonists in the treatment of abnormally elevated intraocular pressure, especially in the prevention and treatment of pathological damage such as in glaucoma.
• the invention is concerned with the use of the compounds of structural formula: or an ophthalmologically acceptable salt thereof wherein n is o or 1.
• Glaucoma is an ocular disorder associated with elevated ocular pressures which are too high for normal ocular activity and may reuslt in irreversible loss of visual function. If untreated, glaucoma may eventually lead to blindness. Ocular hypertension. i.e., the condition of elevated intraocular pressure without optic nerve head damage or characteristic glaucomatous visual field defects, is now believed by many ophthalmologists to represent the earliest phase of glaucoma.
• the novel method of treatment of this invention comprises the topical ocular administration to a patient in need of such treatment of an effective intraocular pressure lowering amount of a dopamine agonist.
• R 1 is C 1-4 alkyl, especially ethyl, and that R 3 is hydrogen. It is even more preferred that R 2 , R 3 and R 4 all be hydrogen.
• a preferred species is trans-4, 6, 6a, 8, 9, 10a-hexahydro-7-ethyl-7H - indolo[3,4:g,h] [1,4]-benzoxazine.
• R 5 is C 1-4 alkyl, especially ethyl or n-propyl, and one or more of R 6 , R 7 , Rand R are hydroxy, methoxy, acetoxy or pivaloyloxy, especially wherein R 9 is hydroxy, methoxy, acetoxy or pivaloyloxy.
• a preferred species is trans-la, 2, 3, 4a, 5, 6-hexahydro-9-hydroxy-4-n-propyl-4H-naphth[1,2,b]-1,4-oxazine.
• An effective intraocular pressure lowering amount of the dopamine agonist, applied topically comprises about 0.5 ⁇ g to 250 ug preferably about 5 ug to 100 ⁇ g per eye on a one to three times a day regimen.
• the pharmaceutical preparation which contains the active compound conveniently may be admixed with a non-toxic pharmaceutical organic carrier, or with a non-toxic pharmaceutical inorganic carrier.
• a non-toxic pharmaceutical organic carrier or with a non-toxic pharmaceutical inorganic carrier.
• pharmaceutically acceptable carriers are, for example, water, mixtures of water and water-miscible solvents such as lower alkanols or aralkanols, vegetable oils, polyalkylene glycols, petroleum based jelly, ethyl cellulose, ethyl oleate, carboxymethylcellulose, polyvinylpyrrolidone, isopropyl myristate and other conventionally employed acceptable carriers.
• the pharmaceutical preparation may also contain non-toxic auxiliary substances such as emulsifying, preserving, wetting agents, bodying agents and the like, as for example, polyethylene glycols 200, 300, 400 and 600, carbowaxes 1,000, 1,500, 4,000, 6,000 and 10,000, antibacterial components such as quaternary ammonium compounds, phenylmercuric salts known to have cold sterilizing properties and which are non-injurious in use, thimerosal, methyl and propyl paraben, benzyl alcohol, phenylethanol, buffering ingredients such as sodium chloride, sodium borate, sodium acetate, gluconate buffers, and other conventional ingredients such as sorbitan monolaurate, triethanolamine oleate, polyoxyethylene sorbitan monopalmitate, dioctyl sodium sulfosuccinate, monothioglycerol, thiosorbitol, ethylenediamine tetracetic acid, and the like.
• auxiliary substances such as e
• suitable ophthalmic vehicles can be used as carrier media for the present purpose including conventional phosphate buffer vehicle systems, isotonic boric acid vehicles, isotonic sodium chloride vehicles, isotonic sodium borate vehicles, aqueous gel vehicles and the like.
• the drug is present in such vehicles in an amount of from 0.01 to about 2% by weight or more.
• the drug is present in an amount of from about 0.05 to 1% by weight.
• the dopamine agonist can be included with a non-bioerodible insert, i.e. one which after dispensing the drug remains essentially intact, or a bioerodible insert, i.e. one that either is soluble in lacrimal fluids, or otherwise disintegrates.
• a solid water soluble polymer as the carrier for the medicament.
• the polymer used to form the insert may be any water soluble non-toxic polymer, for example, cellulose derivatives such as methylcellulose, sodium carboxymethyl cellulose, or a hydroxy lower alkyl cellulose such as hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose and the like; acrylates such as polyacrylic acid salts, ethyl acrylates, polyacrylamides; natural products such as gelatin, alginates, pectins, tragacanth, karaya, chondrus, agar, acacia; the starch derivatives such as starch acetate, hydroxyethyl starch ethers, hydroxypropyl starch, as well as other synthetic derivatives such as polyvinyl alcohol, polyvinyl pyrrolidone, polyvinyl methyl ether, polyethylene oxide, neutralized carbopol and xanthan gum,
• the compound, phosphate buffer salts, and benzalkonium chloride are added to and admixed with water.
• the pH of the resulting admixture is adjusted to 6.8 and the final formulation diluted to volume.
• the formulation is rendered sterile by appropriate means, such as starting the preparative procedure with sterile components and proceeding under sterile conditions, irradiating or autoclaving the finished formulation, or the like.
• the compound and the petrolatum are aseptically combined.
• Ophthalmic inserts are manufactured from compression molded films which are prepared on a Carver Press by subjecting the powdered mixture of the above ingredients to a compressional force of 12,000 lbs. (gauge) at 300°F for one to four minutes. The film is cooled under pressure by having cold water circulate in the platen. Ophthalmic inserts are then individually cut from the film with a rod-shaped punch. Each insert is placed into a vial, which is then placed in a humidity cabinet (88% R.H. at 30°C) for two to four days. After removal from the humidity cabinet, the vials are stoppered and then capped. The vials containing the hydrate insert are then autoclaved at 250°F for 1/2 hour.
• Ophthalmic inserts are manufactured from a solvent cast film prepared by making a viscous solution of the powdered ingredients listed above using methanol as the solvent. The solution is placed on a Teflon plate and allowed to dry at ambient conditions. After drying, the film is placed in an 88% R. H. cabinet until it is pliable. Appropriately sized inserts are cut from the film.
• Ophthalmic inserts are manufactured from a solvent cast film which is prepared by making a viscous solution of the powdered blend of the above ingredients using a methanol/water solvent system (10 ml. methanol is added to 2.5 g. of the powdered blend, to which 11 ml. of water (in three divided portions) is added. The solution is placed on a Teflon plate and allowed to dry at ambient conditions. After drying, the film is placed in an 88% R. H. cabinet until it is pliable. Appropriately sized inserts are then cut from the film.
• Ophthalmic inserts are manufactured from compression molded films which are prepared on a Carver Press by subjecting the powdered mixture of the above ingredients to a compressional force of 12,000 lbs. (gauge) at 350°F for one minute. The film is cooled under pressure by having cold water circulate in the platen. Ophthalmic inserts are then individually cut from the film with a punch. Each insert is placed into a vial, which is then placed in a humidity cabinet (88% R. H. at 30°C) for two to four days. After removal from the humidity cabinet, the vials are stoppered and then capped. The vials containing the hydrated insert are then autoclaved at 250°F for one-half hour.
• the solid inserts of this invention are available for use by the patient in a pathogen free condition.
• the sterilization is preferably conducted after packaging.
• the best mode of sterilizing is to employ ionizing irradiation including irradiation emanating from Cobalt 60 or high energy electron beams.
• the drops heretofore described in Example 1, are used in the usual way employing one to two drops per eye per patient per day. When inserts are employed usually one insert per patient per eye per day is satisfactory. Elevated intraocular pressure is a condition that must be carefully monitored on an individual basis. Thus an intraocular pressure lowering amount can be as little as 0.001 - 0.01 mg to as much as 0.100 - 0.250 mg per eye per patient per day of active medicament. As the individual differences between patient drug response are encountered and as experience with the medicament increases and information accumulates because of a larger patient population being developed, the daily ocular dose for the median population group can be stated with greater statistical accuracy. It may well be found that only a few patients respond to the minimal dose, and then only for a transient period. Also only a few patients may require administration of the drug at the higher dosage ranges. The dose also may be divided for administration. Thus, the quantities set forth previously can be administered in a course of individual deliveries comprising 1-4 or more times per day.
• concentration of active drug in any formulation can vary within a wide range.
• desired dose of formulation will consequently vary for example from a single drop or insert or multiple drops or inserts or larger or smaller inserts.

Applications Claiming Priority (2)

Publications (2)

Family

ID=25212059

Family Applications (1)

Country Status (2)

Cited By (1)

Families Citing this family (2)

Family Cites Families (6)

• 1985
  • 1985-12-24 US US06/813,323 patent/US4774243A/en not_active Expired - Fee Related
• 1986
  • 1986-12-16 EP EP86309814A patent/EP0227416A3/fr not_active Withdrawn

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events